Rossby Financial LCC Purchases New Shares in Recursion Pharmaceuticals, Inc. $RXRX

Rossby Financial LCC purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 28,000 shares of the company’s stock, valued at approximately $142,000.

A number of other large investors also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Recursion Pharmaceuticals by 183.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock worth $33,901,000 after acquiring an additional 4,149,346 shares during the period. Bank of New York Mellon Corp raised its position in Recursion Pharmaceuticals by 1.5% in the first quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company’s stock worth $4,566,000 after acquiring an additional 12,588 shares during the period. Sequoia Financial Advisors LLC bought a new stake in Recursion Pharmaceuticals in the first quarter worth about $67,000. Advisors Asset Management Inc. raised its position in Recursion Pharmaceuticals by 753.8% in the first quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company’s stock worth $706,000 after acquiring an additional 117,851 shares during the period. Finally, GAMMA Investing LLC raised its position in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares during the period. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.25.

Recursion Pharmaceuticals Price Performance

RXRX opened at $5.91 on Wednesday. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -3.32 and a beta of 0.91. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $5.21 and a 200-day moving average price of $5.21. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million during the quarter, compared to analysts’ expectations of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.40) EPS. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider owned 668,197 shares in the company, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.43% of the stock is owned by insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.